MEIP-- i think it's just bouncing around in a double-bottoming process begun when it first plunged on news of share-offering in early Dec. Maybe BofA/MLynch, which led the offering, is keeping it low for a bit to get more investors before letting it zoom back up to $5 or $6 level or higher, especially as we get closer to March news.
A lot of biotechs seem to have been really hammered, not only by late 2014 tax-loss selling, but also pummeled again around Jan. 11-13 when it was clear that there was not going to be much of a "January (buying) effect" and the skittish markets slammed into a "Risk OFF" sentiment. I saw many on my watchlist plummet 10-20%, MEIP one of them. Gave me a chance to buy a few stocks very cheap.
News 
Market Data 
Discover 
